The AMYPAD Diagnostic and Patient Management Study (DPMS) selected and followed-up a memory clinic population suspected of possible Alzheimer's disease (AD), focussing on those with subjective cognitive decline (SCD), mild cognitive impairment (MCI) and dementia where Alzheimer's disease is in the differential diagnosis, to determine the usefulness of β-amyloid imaging with regards to diagnostic confidence, decision trees, change in diagnosis, and alterations between planned and actual patient management plans.
844 subjects recruited in 3 strata (Recruitment ended on 30 October 2020)
(245 SCD plus, 341 MCI, 258 dementia possibly due to AD)
Download the study design paper published in the journal Alzheimer's & Dementia here
Endpoints
Recruitment status (as August 31th, 2021)
The DPMS study succeeded in recruiting 844 of the planned 900 participants when recruitment was formally ended on 30 October 2020. A total of 245 people with SCD, 342 with MCI and 258 with dementia had been enrolled. The different sites completed all remaining visits and scans during the month of June 2021. All sites have been monitored and closed. The quality check of the dataset is complete.
This project has received funding from the Innovative Medicines Initiative 2 Joint undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
